PriMera Scientific Surgical
Research and Practice
Volume 7 Issue 1 January 2026
DOI: 10.56831/PSSRP-07-237
ISSN: 2836-0028

PriMera Scientific Publications

A Multimodal Metabolic and Neurœndocrine Approach to Polytrauma Syndrome: A Proposed Integrative Protocol Incorporating Hyperbaric Oxygen Therapy and Hormonal Optimization

Type: Mini Research Article
Received: December 15, 2025
Published: December 31, 2025

Citation:
K Paul Stoller. "A Multimodal Metabolic and Neuroendocrine Approach to Polytrauma Syndrome: A Proposed Integrative Protocol Incorporating Hyperbaric Oxygen Therapy and Hormonal Optimization". PriMera Scientific Surgical Research and Practice 7.1 (2026): 21-24.

K Paul Stoller*

Fellow, American College of Hyperbaric Medicine, USA

***Corresponding Author:** K Paul Stoller, MD, Fellow, American College of Hyperbaric Medicine, USA.

Abstract

Polytrauma syndrome, particularly among military veterans and individuals with traumatic brain injury (TBI), is associated with complex neuropsychiatric, metabolic, and neuroendocrine dysfunction. Conventional treatment approaches often focus on isolated symptoms rather than underlying systems-level dysregulation. This paper proposes a comprehensive integrative clinical protocol addressing neuro-metabolic dysfunction, neuroendocrine abnormalities, and cerebral hypometabolism in patients with polytrauma syndrome. The approach integrates hormonal assessment and optimization, metabolic support, and low-pressure hyperbaric oxygen therapy (HBOT). This framework is presented as a hypothesis-generating model aimed at improving outcomes in a population with persistently high morbidity and mortality.

Introduction

Traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) frequently coexist, particularly in military and contact-sport populations. Increasing evidence suggests that such patients often suffer not only from structural or functional brain injury, but also from ***neuro-metabolic and neuroendocrine dysfunction***, including hypothalamic-pituitary axis impairment [1-3].

Hypopituitarism following TBI has been reported in 20-50% of patients depending on severity and timing of assessment [4]. These abnormalities may contribute significantly to persistent symptoms such as depression, anxiety, fatigue, cognitive impairment, and suicidality [5].

Neuroendocrine Dysfunction in Polytrauma

Damage to the hypothalamic-pituitary axis following TBI is well documented [4, 6]. Common abnormalities include deficiencies in:

- Testosterone and luteinizing hormone.
- Growth hormone.
- Oxytocin.

- Dysregulated vitamin D metabolism.

Hypogonadism following TBI has been associated with worsened mood, impaired cognition, reduced motivation, and decreased quality of life [7, 8].

Oxytocin plays a critical role in fear modulation, limbic regulation, and emotional processing, with emerging evidence supporting its involvement in trauma-related psychopathology [9-11].

Proposed Diagnostic Evaluation

A comprehensive metabolic and hormonal evaluation is proposed for patients presenting with polytrauma syndrome, including:

- Total and free testosterone.
- Dihydrotestosterone (DHT).
- Estradiol.
- Luteinizing hormone.
- Vitamin D (25-hydroxyvitamin D).
- Hemoglobin A1c.
- Standard metabolic and inflammatory markers.

This approach aligns with recommendations recognizing post-TBI hypopituitarism as an underdiagnosed but clinically significant condition [4, 6].

Hormonal and Metabolic Interventions

Oxytocin

Intranasal oxytocin has demonstrated anxiolytic effects, modulation of amygdala activity, and facilitation of trauma processing in both animal models and human studies [9-12]. Its use is proposed as an adjunctive therapy in appropriate patients, excluding pregnancy and active opioid dependence due to known contraindications.

Gonadal Axis Support

Secondary hypogonadism may be addressed using ***enclomiphene***, a selective estrogen receptor modulator that increases endogenous luteinizing hormone and testosterone production [13]. Although not FDA-approved, enclomiphene has demonstrated efficacy in restoring testosterone levels while preserving spermatogenesis [14].

Monitoring of:

- DHT (to mitigate prostate-related risks).
- Estradiol (to prevent estrogen excess).

is essential. Aromatase inhibitors such as ***anastrozole*** may be considered when clinically indicated [15].

Metabolic Support

For patients with insulin resistance or elevated HbA1c, ***berberine*** has demonstrated glucose-lowering effects through AMPK activation and mTOR inhibition, mechanisms similar to metformin [16-18]. Meta-analyses suggest comparable glycemic efficacy with improved gastrointestinal tolerability in some populations [17].

Hyperbaric Oxygen Therapy for Brain Injury

Hyperbaric oxygen therapy has been shown to enhance cerebral metabolism, mitochondrial function, angiogenesis, and neuroplasticity in both animal models and human studies of TBI [19-22].

Low-pressure HBOT protocols (1.3-1.5 ATA) have demonstrated improvements in cerebral blood flow, cognitive performance, and post-concussive symptoms in chronic TBI populations [21-24].

This protocol proposes:

- 1.5 ATA.
- 60 minutes per session.
- Once daily.
- Two cycles of 40 sessions.

Screening for Neuroinfectious Contributors

Spirochetal infections, including *Borrelia* species, can involve the central nervous system and are known anaerobic or microaerophilic organisms [25, 26]. Screening prior to HBOT may be considered to reduce inflammatory reactions during hyperoxic exposure and resulting cytokine response.

Cognitive Enhancement Post-HBOT

Modafinil has demonstrated efficacy in improving attention, executive function, and wakefulness in patients with TBI and neurological fatigue without the addictive potential of amphetamines [27-29]. It may support cortical metabolic demand following HBOT-induced neuroplastic changes.

Discussion

This protocol reflects a ***systems-biology approach*** to polytrauma syndrome, integrating neuroendocrine, metabolic, and neuroenergetic domains. Current standard care often compartmentalizes these systems, potentially overlooking synergistic therapeutic opportunities.

While regulatory, logistical, and institutional barriers exist, the persistent morbidity associated with polytrauma warrants structured exploration of integrative approaches. This paper does not assert definitive efficacy but proposes a biologically plausible framework for clinical implementation.

Conclusion

Polytrauma syndrome represents a complex multisystem disorder inadequately addressed by symptom-based care alone. Integrating hormonal optimization, metabolic support, and hyperbaric oxygen therapy may improve functional outcomes and quality of life. Given the ongoing burden of TBI-related disability and suicide, the implimentation of such multimodal approaches is ethically and clinically justified.

References

1. McAllister TW. “Neurobiological consequences of traumatic brain injury”. Dialogues Clin Neurosci 13.3 (2011): 287-300.
2. Stein MB., et al. “PTSD and TBI comorbidity”. Am J Psychiatry (2012).
3. Bigler ED. “Neuroimaging biomarkers in mild traumatic brain injury (mTBI)”. Neuropsychol Rev 23.3 (2013): 169-209.
4. Schneider HJ., et al. “Hypopituitarism after traumatic brain injury”. Lancet (2007).
5. Bombardier CH., et al. “Suicide risk after TBI”. Arch Phys Med Rehabil (2010).

6. Tanriverdi F., et al. “Pituitary dysfunction after brain injury”. Endocr Rev (2015).
7. Wagner AK., et al. “Testosterone deficiency after TBI”. J Neurotrauma (2010).
8. Agha A and Thompson CJ. “Anterior pituitary dysfunction following TBI”. Clin Endocrinol 64.5 (2006): 481-8.
9. Meyer-Lindenberg A., et al. “Oxytocin and social cognition”. Nat Rev Neurosci (2011).
10. Koch SBJ., et al. “Oxytocin and fear regulation”. Biol Psychiatry (2016).
11. Flanagan JC., et al. “Oxytocin in PTSD”. Psychoneuroendocrinology (2018).
12. Olff M. “The role of oxytocin in PTSD”. Eur J Psychotraumatol (2012).
13. Kaminetsky J., et al. “Enclomiphene for secondary hypogonadism”. BJU Int (2013).
14. Wiehle RD., et al. “Enclomiphene citrate restores testosterone”. Andrology (2014).
15. Leder BZ., et al. “Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels”. J Clin Endocrinol Metab 89.3 (2004): 1174-80.
16. Turner N., et al. “Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action”. Diabetes 57.5 (2008): 1414-8.
17. Yin J., et al. “Berberine meta-analysis”. Metabolism (2008).
18. Cicero AFG., et al. “Berberine clinical effects”. Nutrients (2019).
19. Harch PG., et al. “HBOT for chronic brain injury”. Med Gas Res (2012).
20. Tal S., et al. “Hyperbaric oxygen neuroplasticity”. PLoS One (2015).
21. Boussi-Gross R., et al. “HBOT in chronic TBI”. PLoS One (2013).
22. Hadanny A., et al. “Hyperbaric oxygen therapy for brain repair”. Nat Rev Neurol (2020).
23. Wolf EG., et al. “Low-pressure HBOT in mild TBI”. Undersea Hyperb Med (2012).
24. Miller RS., et al. “Cerebral perfusion changes with HBOT”. J Neurotrauma (2015).
25. Rupprecht TA., et al. “Neuroborreliosis”. Lancet Neurol (2008).
26. Fallon BA., et al. “CNS Lyme disease”. Am J Psychiatry (1998).
27. Jha A., et al. “Modafinil in neurological disorders”. CNS Drugs (2008).
28. Kaiser PR., et al. “Modafinil after TBI”. J Clin Psychopharmacol (2010).
29. Teitelman E. “Modafinil cognitive effects”. Neuropsychiatr Dis Treat (2006).